| 148.56 2.99 (2.05%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 185.27 | 1-year : | 195.63 |
| Resists | First : | 158.62 | Second : | 167.5 |
| Pivot price | 153.46  |
|||
| Supports | First : | 144.25 | Second : | 120.02 |
| MAs | MA(5) : | 149.54 |
MA(20) : | 155.75 |
| MA(100) : | 152.81  |
MA(250) : | 163.64 |
|
| MACD | MACD : | -2.9 |
Signal : | -2 |
| %K %D | K(14,3) : | 11.3 |
D(3) : | 11 |
| RSI | RSI(14): 40.2 |
|||
| 52-week | High : | 230.02 | Low : | 91.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CRL ] has closed above bottom band by 20.7%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 149.52 - 150.51 | 150.51 - 151.4 |
| Low: | 142.87 - 144.13 | 144.13 - 145.28 |
| Close: | 146.6 - 148.6 | 148.6 - 150.41 |
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Fri, 26 Sep 2025
Charles River Laboratories International (NYSE:CRL) Updates FY 2025 Earnings Guidance - MarketBeat
Thu, 25 Sep 2025
Riverbridge Partners LLC Has $20.28 Million Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Wed, 24 Sep 2025
Assenagon Asset Management S.A. Acquires 11,408 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Wed, 24 Sep 2025
Is Charles River Laboratories Stock Underperforming The Nasdaq? - Barchart.com
Sun, 21 Sep 2025
How Charles River Laboratories’ CFO Transition and Maintained Outlook May Shift Its Investment Story (CRL) - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 49 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 105.6 (%) |
| Shares Short | 2,670 (K) |
| Shares Short P.Month | 2,190 (K) |
| EPS | -1.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 68.13 |
| Profit Margin | -1.7 % |
| Operating Margin | 16.6 % |
| Return on Assets (ttm) | 4.3 % |
| Return on Equity (ttm) | -1.9 % |
| Qtrly Rev. Growth | 0.6 % |
| Gross Profit (p.s.) | 28.65 |
| Sales Per Share | 81.89 |
| EBITDA (p.s.) | 19.42 |
| Qtrly Earnings Growth | -39.1 % |
| Operating Cash Flow | 787 (M) |
| Levered Free Cash Flow | 706 (M) |
| PE Ratio | -113.41 |
| PEG Ratio | 0 |
| Price to Book value | 2.18 |
| Price to Sales | 1.81 |
| Price to Cash Flow | 9.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|